Can a Nektar rival make it on Nasdaq with a $100M IPO? Synthorx is giving it a shot
After all the hubbub around Nektar’s second-gen take on a pegylated IL-2, is Nasdaq ready for a rival that believes it can do the whole field one better?
Synthorx, a preclinical biotech with primate data that was set up by Avalon, has filed for a $100 million IPO — hoping to catch a wave of excitement that has propelled scores of S-1s this year for early-stage companies.
Like Nektar, Synthorx started out with the knowledge that Proleukin never lived up to its incredible initial promise in cancer, largely because of a bad tox profile highlighted by vascular leak syndrome. And the little biotech has been working on its own alternative under the guidance of CEO Laura Shawver, an experienced biotech vet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.